[go: up one dir, main page]

PE20120049A1 - Derivados de 3-anilino-tieno[3, 2-c]piridina como inhibidores de quinasa mek - Google Patents

Derivados de 3-anilino-tieno[3, 2-c]piridina como inhibidores de quinasa mek

Info

Publication number
PE20120049A1
PE20120049A1 PE2011001541A PE2011001541A PE20120049A1 PE 20120049 A1 PE20120049 A1 PE 20120049A1 PE 2011001541 A PE2011001541 A PE 2011001541A PE 2011001541 A PE2011001541 A PE 2011001541A PE 20120049 A1 PE20120049 A1 PE 20120049A1
Authority
PE
Peru
Prior art keywords
inhibitors
alkyl
aniline
pyridine
derivatives
Prior art date
Application number
PE2011001541A
Other languages
English (en)
Inventor
Stephen Price
Karen Williams
Pascal Pierre Savy
Hazel Joan Dyke
John Gary Montana
Mark S Stanley
Liang Bao
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38800915&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120049(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20120049A1 publication Critical patent/PE20120049A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE AZABENZOTIOFENIL DE FORMULA (I) DONDE Z1 ES CR1; Z2 ES N; Z3 ES CR3; Z4 ES CR4, EN DONDE R1, R3 Y R4 SON CADA UNO H, HALO, CN, CF3, NO2, ENTRE OTROS; W ES NX1R5 O OR11, EN DONDE R5 Y R6 SON CADA UNO H O ALQUILO(C1-12); X1 ES OR11 O R11, DONDE R11 ES H, ALQUILO(C1-C12), ALQUENILO(C2-C8), ENTRE OTROS; X2 ES FENILO OPCIONALMENTE SUSTITUIDO CON HALOGENO O SR16, EN DONDE R16 ES H, ALQUILO(C1-C12) O ALQUENILO(C2-C8). TAMBIEN SE REFIERE A UNA COMPOSION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ACTIVIDAD DE LA QUINASA MEK SIENDO UTILES EN EL TRATAMIENTO DE CANCER, ARTRITIS REUMATOIDE
PE2011001541A 2006-08-21 2007-08-21 Derivados de 3-anilino-tieno[3, 2-c]piridina como inhibidores de quinasa mek PE20120049A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83916306P 2006-08-21 2006-08-21
US87160006P 2006-12-22 2006-12-22
US91762407P 2007-05-11 2007-05-11

Publications (1)

Publication Number Publication Date
PE20120049A1 true PE20120049A1 (es) 2012-02-16

Family

ID=38800915

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2007001134A PE20081359A1 (es) 2006-08-21 2007-08-21 Compuestos de azabenzotiofenil como inhibidores de la quinasa mek
PE2011001541A PE20120049A1 (es) 2006-08-21 2007-08-21 Derivados de 3-anilino-tieno[3, 2-c]piridina como inhibidores de quinasa mek

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2007001134A PE20081359A1 (es) 2006-08-21 2007-08-21 Compuestos de azabenzotiofenil como inhibidores de la quinasa mek

Country Status (16)

Country Link
US (1) US7893085B2 (es)
EP (1) EP2069359B1 (es)
JP (1) JP5349306B2 (es)
KR (1) KR101475088B1 (es)
AR (1) AR062469A1 (es)
AU (1) AU2007286807B2 (es)
BR (1) BRPI0714629A2 (es)
CA (1) CA2660963A1 (es)
CL (1) CL2007002431A1 (es)
ES (1) ES2528797T3 (es)
IL (1) IL197060A (es)
MX (1) MX2009001875A (es)
NO (1) NO20091198L (es)
PE (2) PE20081359A1 (es)
TW (1) TWI426078B (es)
WO (1) WO2008024724A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2660546A1 (en) * 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
JP5651125B2 (ja) 2008-12-10 2015-01-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｅｋ阻害剤に対する耐性を付与するｍｅｋ突然変異
EP2538943B1 (en) 2010-02-25 2016-03-30 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
BR112012022801B8 (pt) 2010-03-09 2019-10-29 Dana Farber Cancer Inst Inc método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
CA2871270A1 (en) 2012-05-02 2013-11-07 Lupin Limited Substituted pyridine compounds as crac modulators
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
EP2916859B1 (en) 2012-11-02 2017-06-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
WO2015196072A2 (en) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
EP3394056B1 (en) 2015-12-22 2021-04-14 Shy Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
JP2019518426A (ja) 2016-04-15 2019-07-04 ジェネンテック， インコーポレイテッド がんの診断及び治療方法
FI3624796T3 (fi) 2017-05-19 2025-06-11 Nflection Therapeutics Inc Pyrrolopyridiinianiliiniyhdisteitä ihosairauksien hoitoon
JP7237941B2 (ja) * 2017-05-19 2023-03-13 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置用の融合複素環式芳香族アニリン化合物
MX2019014875A (es) 2017-06-21 2021-01-29 SHY Therapeutics LLC Compuestos que interaccionan con la superfamilia ras para el tratamiento de cancer, enfermedades inflamatorias, rasopatias y enfermedad fibrotica.
TWI827550B (zh) 2017-09-08 2024-01-01 美商建南德克公司 癌症之診斷及治療方法
EP3752200A1 (en) 2018-02-13 2020-12-23 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
KR20250044476A (ko) 2018-07-09 2025-03-31 베링거잉겔하임베트메디카게엠베하 구충성 헤테로시클릭 화합물
CN113473978B (zh) 2018-11-20 2025-03-28 恩福莱克逊治疗有限公司 用于治疗皮肤疾病氰基芳烃-苯胺化合物
CN113498340A (zh) 2018-11-20 2021-10-12 恩福莱克逊治疗有限公司 用于治疗皮肤疾病噻吩基苯胺化合物
CA3120337A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
CN113825543B (zh) 2019-03-19 2024-09-06 勃林格殷格翰动物保健有限公司 驱虫的氮杂-苯并噻吩和氮杂-苯并呋喃化合物
JP2023528822A (ja) 2020-05-29 2023-07-06 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド 駆虫性複素環式化合物
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
EP4426699A1 (en) 2021-11-01 2024-09-11 Boehringer Ingelheim Vetmedica GmbH Anthelmintic pyrrolopyridazine compounds
WO2024033381A1 (en) 2022-08-10 2024-02-15 Vib Vzw Inhibition of tcf4/itf2 in the treatment of cancer

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328920A (en) 1991-04-17 1994-07-12 Hoechst-Roussel Pharmaceuticals Incorporated Substituted (pyridinylamino)-indoles
CA2110514A1 (en) 1991-07-05 1993-01-21 Raymond Baker Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
US5214204A (en) 1991-07-19 1993-05-25 Abbott Laboratories Arylamidoalkyl-n-hydroxyurea compounds having lipoxygenase inhibitory activity
US5403843A (en) 1991-08-12 1995-04-04 Takeda Chemical Industries, Ltd. Pyrrolopyrimidinyalglutaminate derivatives and their use
EP0545478A1 (en) 1991-12-03 1993-06-09 MERCK SHARP & DOHME LTD. Heterocyclic compounds as tachykinin antagonists
JPH05345780A (ja) 1991-12-24 1993-12-27 Kumiai Chem Ind Co Ltd ピリミジンまたはトリアジン誘導体及び除草剤
US5852046A (en) 1993-08-03 1998-12-22 Hoechst Aktiengesellschaft Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them
US5350748A (en) 1993-08-18 1994-09-27 Warner-Lambert Company 3-thio or amino substituted-benzo[b]thiophene-2-carboxamides and 3-oxygen, thio, or amino substituted-benzofuran-2-carboxamides as inhibitors of cell adhesion
DE4425609A1 (de) 1994-07-20 1996-01-25 Bayer Ag Benzofuranyl- und Benzothienyloxazolidinone
BR9804865B1 (pt) 1997-04-24 2011-08-23 pesticida 3-(fenil substituìdo)-5-(tienil ou furil)-1,2,4-triazóis, composição para controlar insetos ou ácaros, bem como processo para controlar insetos, ácaros, moscas brancas e afìdios, para proteger plantas de afìdios, ácaros ou insetos.
GB9723590D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
FR2777886B1 (fr) 1998-04-27 2002-05-31 Adir Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AR019178A1 (es) 1998-06-30 2001-12-26 Lilly Co Eli Compuestos de 7-(benzo(b)tiofeno, furan e indolpiridil o tetrahidropiridilo), efectivos sobre sistemas relacionados con la serotonina, composicionesfarmaceuticas formuladas con dichos compuestos; compuestos intermediarios utiles para preparar dichos compuestos de tiofeno, furan e indolpiridilo otetr
JP2002519321A (ja) 1998-06-30 2002-07-02 イーライ・リリー・アンド・カンパニー セロトニン関連系に効果を有するピロリジン、及び、ピロリン誘導体
JP2002519326A (ja) 1998-06-30 2002-07-02 イーライ・リリー・アンド・カンパニー セロトニン関連系に効果を有するアゼピン誘導体
US6410562B1 (en) 1998-12-18 2002-06-25 Eli Lilly And Company Hypoglycemic imidazoline compounds
JP2000204079A (ja) * 1999-01-13 2000-07-25 Warner Lambert Co ジアリ―ルアミン
BR9916904A (pt) * 1999-01-13 2001-10-30 Warner Lambert Co Benzo heterociclos e seu uso como inibidores demek
FR2799756B1 (fr) 1999-10-15 2001-12-14 Adir Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AR027133A1 (es) 1999-12-30 2003-03-12 Lundbeck & Co As H Derivados de heteroarilo, su preparacion y uso.
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
CN1219753C (zh) 2000-07-19 2005-09-21 沃尼尔·朗伯公司 4－碘苯氨基苯氧肟酸的氧合酯
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US6653346B1 (en) 2002-02-07 2003-11-25 Galileo Pharmaceuticals, Inc. Cytoprotective benzofuran derivatives
EP1476448A2 (en) 2002-02-19 2004-11-17 PHARMACIA & UPJOHN COMPANY Azabicyclic compounds for the treatment of disease
WO2003077855A2 (en) * 2002-03-13 2003-09-25 Array Biopharma, Inc N3 alkylated benzimidazole derivatives as mek inhibitors
IL163995A0 (en) 2002-03-13 2005-12-18 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US20040009976A1 (en) 2002-04-30 2004-01-15 Kumiko Takeuchi Hypoglycemic imidazoline compounds
GB0214268D0 (en) * 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
AU2003257145B2 (en) 2002-08-02 2008-11-13 Merck Sharp & Dohme Corp. Substituted furo (2,3-b) pyridine derivatives
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
JP2005104838A (ja) 2003-01-09 2005-04-21 Tanabe Seiyaku Co Ltd 縮合フラン化合物
GB0316232D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
GB0316237D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
ATE506953T1 (de) 2003-08-07 2011-05-15 Rigel Pharmaceuticals Inc 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
DE10351436A1 (de) 2003-11-04 2005-06-09 Merck Patent Gmbh Verwendung von Thienopyrimidinen
DE602004011985T2 (de) 2003-11-25 2009-03-05 Eli Lilly And Co., Indianapolis Modulatoren des peroxisomproliferatoraktivierten rezeptors
BRPI0417833A (pt) 2003-12-19 2007-04-17 Biovitrum Ab novos derivados de benzofurano, os quais podem ser usados na profilaxia ou tratamento de distúrbios relacionados com o receptor 5-ht6
EP1894917B1 (en) 2003-12-22 2010-01-20 Basilea Pharmaceutica AG Aryloxy- and arylthioxyacetophenone-type compounds for the treatment of cancer
JP2007516275A (ja) 2003-12-23 2007-06-21 ファイザー・プロダクツ・インク 認知増強および精神病性障害のための治療的組合せ
JP2008534664A (ja) * 2005-04-06 2008-08-28 アストラゼネカ アクチボラグ 置換複素環およびｃｈｋ１、ｐｄｋ１及びｐａｋ阻害剤としてのそれらの使用
CN101305010A (zh) 2005-09-01 2008-11-12 阿雷生物药品公司 Raf抑制剂化合物及其用法
CA2660546A1 (en) 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
WO2008028141A2 (en) 2006-08-31 2008-03-06 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof

Also Published As

Publication number Publication date
WO2008024724A1 (en) 2008-02-28
TW200823222A (en) 2008-06-01
EP2069359B1 (en) 2014-11-12
EP2069359A1 (en) 2009-06-17
AR062469A1 (es) 2008-11-12
CA2660963A1 (en) 2008-02-28
AU2007286807A1 (en) 2008-02-28
IL197060A (en) 2014-12-31
NO20091198L (no) 2009-05-20
JP5349306B2 (ja) 2013-11-20
JP2010501584A (ja) 2010-01-21
MX2009001875A (es) 2009-03-02
PE20081359A1 (es) 2008-11-27
TWI426078B (zh) 2014-02-11
IL197060A0 (en) 2009-11-18
BRPI0714629A2 (pt) 2013-05-07
US7893085B2 (en) 2011-02-22
US20080081821A1 (en) 2008-04-03
KR101475088B1 (ko) 2014-12-23
KR20090047538A (ko) 2009-05-12
CL2007002431A1 (es) 2008-03-14
ES2528797T3 (es) 2015-02-12
AU2007286807B2 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
PE20120049A1 (es) Derivados de 3-anilino-tieno[3, 2-c]piridina como inhibidores de quinasa mek
PE20091561A1 (es) Compuestos inhibidores de raf y metodos para su uso
PE20091527A1 (es) Derivados de piridazinona
PE20080611A1 (es) Compuestos de azabenzofuranil y metodos de uso
PE20130647A1 (es) Indoles
WO2007149448A3 (en) Pyrazinones as cellular proliferation inhibitors
NO20070731L (no) Heterocykliske forbindelser.
PE20140397A1 (es) Derivados de fluoro-piridinona utiles como agentes antibacterianos
PE20140609A1 (es) Diazacarbazoles y metodos de uso
PE20091175A1 (es) Derivados bis-(sulfonilamino) en terapia 205
PE20061297A1 (es) Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c
PE20090775A1 (es) Nuevos derivados de biarilo
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
PE20121482A1 (es) Derivados de imidazopiridina como inhibidores de jak
PE20090610A1 (es) Derivados de pirazol sustituidos
PE20110424A1 (es) Isoindolonas que inhiben la cinasa mek
PE20131343A1 (es) Derivados de acido benzoico
PL1891029T3 (pl) Związki organiczne do leczenia stanów zapalnych lub alergicznych
PE20140975A1 (es) Derivados de imidazopirazina como inhibidores de syk
PE20090290A1 (es) Derivados de pirrolopiridina como inhibidores de bace
PE20090238A1 (es) Derivados de pirazol como inhibidores de tirosinquinasas
PE20081174A1 (es) Inhibidores de metaloproteasas derivados de heterociclos
PE20110196A1 (es) 5-alquinil-pirimidinas
PE20080038A1 (es) Derivados de tiazolidinadiona como inhibidores de la pi3 quinasa
MA32192B1 (fr) Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed